Research programme: benzopyran-based cancer therapeutics - Novogen

Drug Profile

Research programme: benzopyran-based cancer therapeutics - Novogen

Alternative Names: Cantrixil™; CS-6; SBP therapeutics - Novogen; Super-benzopyran compounds - Novogen; Trilexium (Trx) analogues - Novogen; Trx-1 - Novogen; Trx-2 - Novogen; TRXE 002 1; TRXE-002; TRXE-0025; TRXE-009; TRXE-025

Latest Information Update: 04 Oct 2016

Price : $50

At a glance

  • Originator Novogen
  • Developer Novogen; Weill Cornell Medical College
  • Class Benzopyrans; Small molecules
  • Mechanism of Action Cell cycle inhibitors; EIF 2 kinase inhibitors; Electron transport chain complex protein inhibitors; Glucuronidase modulators; JNK mitogen-activated protein kinase modulators; NADH oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glioblastoma; Malignant melanoma; Neuroblastoma; Ovarian cancer; Prostate cancer
  • Research Brain cancer

Most Recent Events

  • 12 Sep 2016 Novogen plans a phase I trial in Ovarian cancer, Fallopian tube cancer or Peritoneal cancer (Monotherapy, Combination therapy, Second-line therapy or greater) in Australia (NCT02903771)
  • 12 Sep 2016 The US FDA approves IND application for TRXE 002 1 in Ovarian cancer
  • 16 Aug 2016 Novogen files an IND application with the US FDA for TRXE 002 1 in ovarian cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top